Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reata Pharmaceuticals, Inc.

http://www.reatapharma.com/

Latest From Reata Pharmaceuticals, Inc.

Keeping Track: Opdivo, Keytruda Continue Adjuvant Push As Cancer Dominates Recent Applications

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Cancer US FDA Performance Tracker

Reata’s Skyclarys Approval Aided By Natural History And Delayed-Start Analyses

The first treatment for the rare neurodegenerative disorder Friedreich’s ataxia relied on a single placebo-controlled efficacy trial.

US FDA Performance Tracker Rare Diseases

Reata Lays Commercial Path For Skyclarys With First-Ever Friedreich’s Ataxia Nod

The company forecasts an addressable US patient market that comprises 90% of the total Friedreich’s population of 5,000 based on a broad label covering patients aged 16 and older.

Approvals Business Strategies

US FDA Neuroscience Office Director Billy Dunn Departs As Agency Faces New Review Challenges

Dunn is retiring after an 18-year career that included involvement in some high-profile and controversial drug approval decisions, not the least of which is Biogen’s Alzheimer’s treatment Aduhelm; deputy director Teresa Buracchio takes over the neurology office on an acting basis.

FDA Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register